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AB~TRACT 
The gmwth of fresh and tis:;ue cultured B-16 malignant melanoma cells in C57BL/6 mice 
was quuntitated, using a:-. parameters the latent time to tumor appearance, tumor incidence, 
and mortality rate. The tumor wa:-. antigenic. as evidenced by the appearance of humoral 
antibodies to melanoma-associated antigens during the nat ural growth of this tumor and by 
the induction of rel>istance to lethal doses of tumor by immunization with repeated injections 
of irradiated, or sublethal doses of viable, melanoma cells. This immunity was not entirely 
s pecific , since mic-e immunized to B-16 melanoma were slightly rP!-istant to challenge with 
BW102:t~ mammary adenocarcinoma and. conver~ely, mice immunized to mammary 
adenocarcinoma were slightly resistant to melanoma. 
The tmmune res ponses to malignant tumor~ are 
belie,·ed to have a major [1.21. though complex j:~ ]. 
effect em tumor growth . Thu~. tumor antibodies or 
,.,ensitized lymphocytes may inhibit [4- 6] or en-
hance [7-8) tumor growth in vi\'o, and kill [9 1:1 1 or 
protect from kill in!{ r:u I 1.') I tumor cells in vitro. 
The complex effects of tumor immunity on tumor 
growth can best be studied in animal tumor 
models . For this reason we have attempted to 
develop a murine model of human malignant 
melanoma. This tumor was selected because it is 
one of the human cancers in which the presence of 
an immune response to tumor-associated antigens 
has been most amply demonstrated (16 191. 
The experiment!:' which follow indicate that B-16 
melanoma , a transplantahle tumor of murine mel-
anocytes which arose spontaneously in a Cn7RL/ 6 
mouse in 195 1. can sene a!i a model for the studv of 
human malignant melanoma The l{rowth of B-16 
melanoma can be quantttated and the tumor is 
antigenic . 
1\!ATFHIAU.; 1\"0 l\IETHOU!-> 
Mice. Female C57BL/6 mict> (.Jackson Laboratories, 
Bar Harbor, MatneJ were u~ed for all experiments. The 
mice were approxtmatel~ 6 weeks old at the beginmng 
of each experiment. 
Tumors. B-16 malignant melanoma (obtained origi-
nally from Dr. Selma ilagi) and BW10232 mammary 
adenocarcinoma (obtained originally from Jackson Labo-
ratories) were maintained by serial, subcutaneous trans· 
plantation in female C57BL/6 mice. Both tumors arose 
spontaneously in C57BL/6 mice [20 j. 
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Cell .\u.~pensron~. Excised tumors were minced with 
scissors in phosphate-buffered saline CPB ). pH i .3, and 
stramed through a fine stainless-steel mesh. Cells were 
collected by centrifugation (800 x J1 for 6 min) , washed 
twice wtth 40 ml of PBS, and resuspended in 0.5 ml of 
PBS. Red-blood cells and some nonviable tumor cells 
were lysed by osmotic shock resulting from the addition 
of 4 ml of distilled water. After 30 sec. physiologtc 
osmolanty was restored by the addition of 40 ml of PB . 
The cells were pelleted by centrifugation 1800 x g for 6 
min) and resuspended to the desired concentration. 
Viability, as determined by trypan blue exclusion, ranged 
from 1 0- 20't. Over 80% of cells were pigmented and 
presumably melanoma. The proportion of lymphoid cells, 
macrophagcs, or fibroblasts in the cell population was not 
determined. 
Cell culture . R-16 melanoma was established in cul-
ture by plating cell suspensions obtained from minced 
tumor by digestion with CTC (0.1% collagenase, 0.1 '11-
trypsin, and 111( chicken serum in calcium and magne-
sium free Hanks' balanced salt solution) at 37 °C. These 
cells were grown as monolayers in Petri dishes (Falcon 
Plastics, Los Angelel>l tn RPM! 1640 culture medium 
containing JO't fetal calf ;,erum (Grand Island Biological 
Co., Grand Island, New York) plus penicillin ( 100 units/ 
ml), fungizone (100 )'g/ml), and kanamycin (5 )'g/ml) at 
37°C tn a humidified atmosphere of 5"f CO, and air. 
Electron microscoptc studies (kindly performed by Dr. 
David ' tlver~J confirmed that the cells were all melano-
cytic. 
Tumor cell inoculatron . A tenth of a milliliter of tumor 
cell suspensic>n in PB ' was inoculated subcutaneously in 
the midabdomen regton through a 25-gauge needle. 
Presence or absence of tumor:, was determined twice a 
week, and the two largest external diameters were 
measured with calipers. 
Antzmelanoma antrbodies assay . Circulating anti· 
bodies to melanoma-associated antigens were measured 
as described prev10usly [21) by a double-antibody radio-
immunoassay developed in our laboratories. Briefly, 
antigens associated with murine melanoma were radiola-
bE-led by incubating cultures of melanoma cells with 
•H-leurine and the antigens were solubilized by lysmg 
the cells in nonionic detergent. For antibody assay, 
aliquots of the culture medium were incubated with 
dilutions of moube serum, and immune complexes result -
ing from binding of antibody to melanoma-associated 
antigens were precipitated by the addition of an excess of 
goat antimouse immunoglobulin. Previous studies have 
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shown that there is a linear relationship between the 
amount of antimelanoma serum used and specific bind-
ing of rad iolabeled melanoma cultured medium [21). 
RESULT 
Normal Grotl'th of R-16 MPlanoma 
Initial experiments were conducted to define in 
quantitative term~ the ~trowth of B-16 melanoma 
in C57BL/6 mice. These and all subsequent studies 
were conducted in group!; of lO mice. unless 
otherwise specified. Increasinj!; numbers of viable 
melanoma cells obtained from culture or from 
freshly excised melanoma were inoculated sub-
cutaneously. The sub equent presence and size 
of tumors were determined twice weekly. 
Cultured cells. As can be seen in Figure 1. as the 
number of tumor cells inoculated was increased, 
the latent time to tumor appearance decreased and 
tumor incidence and mortality rate increased. 
Increasing the tumor dose from 10• to 2 ' 10" cells 
decreased the average latent time to tumor appear-
ance from over 40 days to 9 days: 30 days post 
tumor inoculation. it increased the tumor inci-
dence from 10<"( to 10011. and decreased survival 
rate from 1W( to a7c;.. Once a tumor appeared, it 
continued to j!;TOW until it killed the mouse. There 
was no evidence of gross metastasis to internal 
organs in random autopsies of dead mice. Sponta-
neous resolution of tumors was not seen in the~e 
experiments. Figure 2 illustrates the growth rate of 
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F1c. 1: Tumor incidence and survival rate in groups of 
10 C57Bl16 m1ce, following inoculation of varying num-
bers of B-16 melanoma cells obtained from tissue culture. 
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F1c. 2: Growth of 8 -16 melanoma in individual mice 
following inoculation of C57BL/6 mice with 2 >< to• or 
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F1c. 3: Average growth of B-16 melanoma m groups of 
10 C57BL/6 mice inoculated with varying numbers of 
viable 8-16 melanoma cells obtained from ti sue culture. 
lated with 2 · to• or 1 10" viable melanoma 
cells. Tumors enlarged at similar rate once they 
appeared, regardless of the size of the initial cell 
inoculum. There was a correlation between average 
tumor size and tumor cell dose during the early but 
not in the late phase of tumor growth (Fig. 3). 
Figure 4 compares tumor incidence versus tumor 
dose in separate experiments. Two experiments 
were conducted one month apart using separate 
batches of the same I ine of cultured melanoma 
cells and two separate shipments of 6-week-old 
female Ci17BL/6 mice. Though a relationship was 
present between increasing tumor dose and in-
creasing tumor incidence in both experiments. the 
actual incidence of tumor with a particular dose of 
tumor cells differed. 
Fre.\h tumor cel/8. Experiments similar to those 
described above were conducted with tumor cells 
obtained from freshly excised melanoma. A similar 
relationship was observed between increasing 
tumor dose, decreasing latent time to tumor ap-
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pearance, increasing tumor incidence, and increas-
ing mortality rate. Increasing tumor dose from 5 , 
101 to 2 x 101 viable cells decreased the average 
latent time to tumor appearance from 22 to 4 days, 
and 30 days after tumor inoculation increa!:>ed 
tumor incidence from 67Cf to IOO"f and decreased 
survival rate from 67 '} to O"'c . 
Immunogenicity of B-16 M elanoma 
To determine whether B -L6 melanoma is anti· 
genic, groups of 10 C57BL/6 mice were immunized 
to this tumor using various procedures. One group 
of mice was inoculated with a single subcutaneous 
injection of 2 x 10 1 irradiated (12,000 R) celb, 
another with :1 similar injections given I week 
apart, and a third with 2 nonlethal dose>. of 10• 
viable melanoma cells given I month apart. All 
cells were obtained from freshly excised tumor. All 
three groups, as well as a no~immunized control 
group. were challenged on the same day with 108 
viable melanoma cells obtained from fre. hly ex-
ch.ed tumor tissue. The challenges were admims-
tered 1 week after the last injection of irradiated 
cells and 1 month after the last injection of viable 
cells. 
As can be seen in Table I, mice injected 3 times 
with irradiated cells o r twice with sublethal doses 
of viable cells. were partially resistant to challenge 
with a lethal dose of tumor cells. This resistance 
was evidenced by prolonged latent time to tumor 
appearance, lower incidence of tumors, and lower 
mortality rate. The difference in la tent period and 
in survival rate between these two groups and the 
control group was statistically significant. The,e 
results demonstrate that actiH• immunization of 
syngeneic mice with B· L6 melanoma induces par-
tial immunity to lethal dose;. of thi;, tumor and 
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Frc. 4: Incidence of tumon; 30 days after inoculatwn 
of varying numbers of B-16 melanoma cells into groups ot 
10 C5781)6 mice. Experiments were conducted on two 
separate occasions using different batcheti of the same 
line of cultured melanoma cells and different shipments 
of mice. 
TABLE I 
Active Immunization of C.578L/6J mice to B-16 
melanoma 
Larenl i Tumuri I Su"·i\ali 
lmmuntzatinn' schedule penud 1nridenre 
lda-.) ('.) 
Control 8 .6 100 
Irradiated cells x I 10.6 100 
Irradiated cells x 3 11.4 80 
Viable cells , 2 18 0 
- -
• Croups of9- 10, C57B1)6.J female mice 
t Days for tumor appearance in 50'l of mice 
t 30 days post-tumor inoculation 







To determine the specifrcity of acti"e immuniza-
tion to 8 -16 melanoma, the following experiments 
were conducted. A group of 20 C57BL/ 6 mice was 
injected :i times subcutaneously with 107 irradiated 
B-16 melanoma cells at L-week intervals. This 
immunization schedule had been shown in the 
prior experiment to induce partial immunity to 
lethal doses of melanoma cells . Another group of20 
mice was injected in a similar manner with 107 
irradiated mammary adenocarcinoma cells. and a 
group of 20 untreated mice served as controls. One 
week following the last injection. 10 mice in each 
group were challenged with 1.5 10• viahle 
melanoma cells or with :3 x tO• viable mammary 
adenocarcinoma cells. This dose of mammary 
adenocarcinoma induces tumors in 10()1 , of mice, 
as established in preliminary experiment;.. As can 
be een in Table II, mice immunized with mela-
noma were partially immune to challenge with 
melanoma cells. Mice immunized with mammary 
adenocarcinoma had a slightly increased resistance 
to melanoma as evidence by a small decrease in 
tumor incidence and a small increase in survh·al 
rate. The>.e were not statistically significant. How-
ever, a similar trend was observed in two other 
experiments. In one of the;.e two experiments, prior 
immunization with B-16 melanoma inhibited the 
subsequent growth of mammary adenocarcinoma 
significantly (p < 0 .001 ). These experiments indi-
cate that a slight and variable degree of resistance 
to B -16 melanoma or mammary adenocarcinoma 
can be induced h) immunization with the other 
tumor . 
Hum oral Anllbod' Re~punM! to B-16 M elanoma 
Antibodie, to antigen;. associated with B-16 
melanoma were measured by a recently developed 
radioimmunoa say. The specificity of the anti -
bodies measured by this asRay h as been reported 
previously 121 ]. erum was collected from control 
mice and from groups of mice 1 week after immuni-
zation \dth a single or wrth :J weekly inJections of 
irradiated melanoma cells. As can be ;.een in Table 
111, ;;era of immunited mice bound more radiola-
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TABLE 11 
• pl'CI[iclty uf rmmumzat10n to B-16 melanoma 
lmmun1m1inn ' 'thi!dule 
Lat~n1 t I Tumnr+ I Survi,·alt 
penncl incidence rate 
ldtl\'1 I 'I 1 I 
Control 43 60 
lrradtated melanoma 77 
cells x 3 3_ 
Irradiated mammary ade- > 80 
nocarrinoma ~ :"1 
10 
55 
• Groups of 9 10, C5713ll&J female mice 




tAt termination of experiment (80 days post-tumor 
challenge) 
TABLE Ul 
Melanoma antrbodie.~ rn rmmumzed mrce 
GmuJI 
Control 
immunized w1th Irradiated mela-
noma cells • I 
Immunized with irradiated mela-
noma cells x 3 
• 116.000 CPM per 0.1 ml 















t Average radioactivity bound by triplicate aliquots of 
serum 
t Calculated by dt\•tdmg CPM bound by test serum by 
CPM bound by control serum 
beled melanoma -associated antigen;; I han did nor-
mal mouse sera . Hmding acti\ ity was greate~t in 
mice tmmuni:.:ed with several injections of mela-
noma cells. The higher antibody levels correlated 
with increa~cd resistanee to challenge with lethal 
doses of melanoma cells. 
DISCl SSIO'-
'fhe main linding of this study is that B- 16 
melanoma is immunogenic. as e\'idenced by induc-
tion of: (a) increased resistance to lethal doses of 
melanoma cells. and (b ) circulating antibodie. to 
antigens associated with melanoma by active im -
munization with melanoma cells. 
We have shown that the growth of B-16 mela -
noma can be defined quantitatively using as pa-
rameters the latent time to tumor appearance. 
tumor incidence. and mortality rate. There is a 
direct relations hip bet ween increasing tumor dose 
and decreased latent time to tumor appearance. 
increased tumor incidence. and de<.:reased survival 
rate. These relationships are present whether cul-
tured cells or cells obtained from fre hly excised 
tumor tissue are used. Present!\. undefined varia-
bles in tumor cells and/or rectpient mice result m 
variations in the actual gro\\th rate of a tumor 
when different preparations of cell!; are adminis-
tered to diffe rent batche!> of syngeneic mice . 
B-16 melanoma is immunogenic in the C'iJ7HL/6 
mice in which this tumor arose spontaneously. 
confirming the work of Bartlett [22], Kreider and 
Benjamin (2:11. and Bart et al [24). This immunity 
is evidenced by increased res istance to otherwise 
lethal doses of melanoma cells. and by the presence 
of antihodtes to melanoma-associated antigens. 
We have found that several schedules are effective, 
including repeated immunization ''ith irradiated 
cells or nonlethal doses of viable cells. 
This immunity is not entirely specific. Thus, 
mice immuni7ed with mammary adenocarcinoma 
may al>:o show a s light degree of immunity to 
challenge with melanoma and vice versa . It is not 
possible to determine from our experiments 
"het her this slight and variable immunity repre-
sents a nonspecific adjuvant effect similar to that 
obsen.ed in animals injected with BCG (25- 27] or 
other material [28 ). or whether it repre5ents the 
presence of shared tumor antigens between B-16 
melanoma and BWJ0232 mamma ry adenocar-
cinoma. [t is of mterest that there is growing 
evident·e that both normal and mal ignant tissues 
may share some common antigens. Thus. in mice, 
type C \' ira! group-specific antigens have been 
identified in normal and leukemic cells (29-:HJ. 
Viral part ides have been recently demonstrated 
electron microscopically in the B-16 melanoma 
used in these studies by Dr . David Silvers (per-
sonal communication) . In man, embryonic anti -
gens associated with gastrointestinal malignancies 
[:12] may be found in small amount in normal 
tissue~ (3:1,:14), and pat tents with a variety of 
malignancies may develop antibodies [3:1) or sensi-
tized lymphocytes (36] to antigen, present in 
normal autologous and homologous tissues. 
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